Throughout the COVID-19 pandemic, therapy options—like monoclonal antibody/antiviral medications and mechanical ventilation—have been limited for critically-ill COVID-19 patients. But a new therapy, Seraph 100, is now available. In this sponsored session presented by Sepsis Alliance and sponsored by ExThera Medical, learn about the impact of viremia, innovations in pathogen removal with this commercially-available therapeutic, the latest supporting data and literature, and ongoing clinical research demonstrating the clinical and economic benefits of this therapeutic to a broader septic patient population. Additionally, hear candid commentary from a Seraph 100 user concerning patient identification, timing of initiation, and best practices learned via experience in the ICU, followed by open Q&A.
Sean Phillip Barnett, MD; Anthony Ramage, DO